Nagoya University Hospital - Dept of Otorhinolaryngology Trials

Nagoya University Hospital - Dept of Otorhinolaryngology	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

SIRE, Christian

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

SPINO-RT, NCT06692556: Randomized Comparative Multicenter Phase III Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence

Not yet recruiting

266

Europe

Adjuvant radiotherapy

Centre Leon Berard

Cutaneous Squamous Cell Carcinoma (CSCC)

06/29

PembroMetaRT, NCT04747054: Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Recruiting

102

Europe

Pembrolizumab, KEYTRUDA, Loco-regional radiotherapy, Chemotherapy

UNICANCER, GORTEC, National Cancer Institute, France

Squamous Cell Carcinoma of Head and Neck

10/25

10/29

FRAIL-IMMUNE, NCT03723967: (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

Completed

104

Europe

Durvalumab with Carboplatin/Paclitaxel, Combination of Durvalumab with Carboplatin/Paclitaxel

Centre Leon Berard

Squamous Cell Carcinoma of the Head and Neck

05/20

03/24

OLA-TMZ-RTE-01, NCT03212742 / 2016-003468-38: Phase I/IIa Study of Concomitant Radiotherapy with Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

Active, not recruiting

1/2

Europe

Olaparib, Temozolomide (TMZ), IMRT (Intensity Modulated Radiation Therapy)

Centre Francois Baclesse, National Cancer Institute, France

Malignant Gliomas, Radiotherapy, PARP Inhibitor

09/25

12/25

Liem, Xavier

NANORAY-312, NCT04892173 / 2021-002163-22: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Recruiting

500

Europe, Japan, US, RoW

JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy

Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA

Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged

06/26

06/27

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

PembroMetaRT, NCT04747054: Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Recruiting

102

Europe

Pembrolizumab, KEYTRUDA, Loco-regional radiotherapy, Chemotherapy

UNICANCER, GORTEC, National Cancer Institute, France

Squamous Cell Carcinoma of Head and Neck

10/25

10/29

SinocaRT, NCT05943119: Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery

Recruiting

Europe

Radiotherapy in painting dose on histoscannographic mapping, Standard pan-sinusal Radiotherapy

Centre Francois Baclesse

Tumor, Solid

01/28

03/29

STEREOPOSTOP, NCT03401840: STEREO-POSTOP 01 (PostOperative Hypofractionated Stereotactic Body Radiotherapy ) - GORTEC 2017-03

Completed

N/A

Europe

postoperative hypofractionated stereotactic radiotherapy

Centre Jean Perrin, GORTEC

Head and Neck Neoplasms

09/23

STEREOLIVER, NCT03408665: Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer

Active, not recruiting

N/A

280

Europe

SBRT

Centre Oscar Lambret, Canceropôle Nord Ouest

Liver Cancer, Liver Metastases

12/26

12/27

ETOILE, NCT02838602: Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors

Recruiting

N/A

250

Europe

Carbon ions therapy, Advanced external radiotherapy by Xrays or protons

Hospices Civils de Lyon

Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma

12/26

LAPIERRE, Ariane

ZOSTER, NCT03951493: Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases

Recruiting

225

Europe

Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions, Hypo-fractured radiotherapy in stereotactic conditions

Institut Cancerologie de l'Ouest

Vertebral Metastasis

11/23

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

Nishio, Naoki

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

DISCOVARY, NCT05694819: Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma

Active, not recruiting

Japan

Darolutamide, Goserelin

National Cancer Center Hospital East, Bayer Yakuhin, Ltd.

Salivary Gland Cancer

08/24

03/26

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

SIRE, Christian

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

Not yet recruiting

266

Europe

Adjuvant radiotherapy

Centre Leon Berard

Cutaneous Squamous Cell Carcinoma (CSCC)

06/29

PembroMetaRT, NCT04747054: Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Recruiting

102

Europe

Pembrolizumab, KEYTRUDA, Loco-regional radiotherapy, Chemotherapy

UNICANCER, GORTEC, National Cancer Institute, France

Squamous Cell Carcinoma of Head and Neck

10/25

10/29

FRAIL-IMMUNE, NCT03723967: (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

Completed

104

Europe

Durvalumab with Carboplatin/Paclitaxel, Combination of Durvalumab with Carboplatin/Paclitaxel

Centre Leon Berard

Squamous Cell Carcinoma of the Head and Neck

05/20

03/24

OLA-TMZ-RTE-01, NCT03212742 / 2016-003468-38: Phase I/IIa Study of Concomitant Radiotherapy with Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

Active, not recruiting

1/2

Europe

Olaparib, Temozolomide (TMZ), IMRT (Intensity Modulated Radiation Therapy)

Centre Francois Baclesse, National Cancer Institute, France

Malignant Gliomas, Radiotherapy, PARP Inhibitor

09/25

12/25

Liem, Xavier

NANORAY-312, NCT04892173 / 2021-002163-22: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Recruiting

500

Europe, Japan, US, RoW

JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy

Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA

Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged

06/26

06/27

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

PembroMetaRT, NCT04747054: Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Recruiting

102

Europe

Pembrolizumab, KEYTRUDA, Loco-regional radiotherapy, Chemotherapy

UNICANCER, GORTEC, National Cancer Institute, France

Squamous Cell Carcinoma of Head and Neck

10/25

10/29

SinocaRT, NCT05943119: Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery

Recruiting

Europe

Radiotherapy in painting dose on histoscannographic mapping, Standard pan-sinusal Radiotherapy

Centre Francois Baclesse

Tumor, Solid

01/28

03/29

STEREOPOSTOP, NCT03401840: STEREO-POSTOP 01 (PostOperative Hypofractionated Stereotactic Body Radiotherapy ) - GORTEC 2017-03

Completed

N/A

Europe

postoperative hypofractionated stereotactic radiotherapy

Centre Jean Perrin, GORTEC

Head and Neck Neoplasms

09/23

STEREOLIVER, NCT03408665: Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer

Active, not recruiting

N/A

280

Europe

SBRT

Centre Oscar Lambret, Canceropôle Nord Ouest

Liver Cancer, Liver Metastases

12/26

12/27

ETOILE, NCT02838602: Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors

Recruiting

N/A

250

Europe

Carbon ions therapy, Advanced external radiotherapy by Xrays or protons

Hospices Civils de Lyon

Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma

12/26

LAPIERRE, Ariane

ZOSTER, NCT03951493: Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases

Recruiting

225

Europe

Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions, Hypo-fractured radiotherapy in stereotactic conditions

Institut Cancerologie de l'Ouest

Vertebral Metastasis

11/23

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

Nishio, Naoki

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

DISCOVARY, NCT05694819: Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma

Active, not recruiting

Japan

Darolutamide, Goserelin

National Cancer Center Hospital East, Bayer Yakuhin, Ltd.

Salivary Gland Cancer

08/24

03/26



	Diseases Companies Products Productz Mechanisms of Action Sites